An Open-Label, Single-Arm, Multicenter Study To Assess The Safety Of Vemurafenib In Patients With Braf V600 Mutation Positive Metastatic Melanoma In South Africa.
Phase of Trial: Phase IV
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Roche
- 28 Oct 2019 Status changed from active, no longer recruiting to completed.
- 29 Jan 2018 Planned primary completion date changed from 31 Dec 2018 to 10 Dec 2019.
- 29 Jan 2018 Planned End Date changed from 31 Dec 2018 to 10 Dec 2019.